How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
franchise, deep oncology pipeline, and an intellectual-property runway that extends to 2036. Analysts have also pointed to Gilead's established dividend profile and expanding cell therapy footprint, including its plan to acquire Arcellx for up to US$7.80 billion, as reinforcing the company's appeal to both income-focused and growth-oriented investors. We'll now examine how this renewed analyst optimism, particularly around Gilead's patent protection and HIV portfolio, may influence its investment narrative. Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Gilead Sciences Investment Narrative Recap To own Gilead, you have to believe its HIV franchise and emerging oncology portfolio can offset pricing and competitive pressures, while its long patent runway supports predictable cash flows. The recent wave of upbeat analyst c
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLXBusiness Wire
- Gilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders?PR Newswire
- URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—ACLX, DBRG, AVO, and CVGWGlobeNewswire
- Halper Sadeh LLC is Investigating Whether BCO, THR, ACLX are Obtaining Fair Deals for their ShareholdersGlobeNewswire
ACLX
Earnings
- 2/26/26 - Miss
ACLX
Sec Filings
- 3/6/26 - Form SC
- 3/6/26 - Form SC
- 3/6/26 - Form SCHEDULE
- ACLX's page on the SEC website